BioCryst Pharmaceuticals Reports 8-K Filing

Ticker: BCRX · Form: 8-K · Filed: Oct 14, 2025 · CIK: 882796

Sentiment: neutral

Topics: material-agreement, financial-condition, corporate-governance

Related Tickers: BCRX

TL;DR

BioCryst dropped an 8-K detailing material agreements, financials, and exec changes. Check it out.

AI Summary

BioCryst Pharmaceuticals, Inc. announced on October 14, 2025, several key events including the entry into a material definitive agreement, updates on its results of operations and financial condition, and changes in its officer and director positions. The company also reported on other events and filed financial statements and exhibits.

Why It Matters

This 8-K filing provides crucial updates on BioCryst's financial health, operational status, and corporate governance, which are important for investors to assess the company's trajectory.

Risk Assessment

Risk Level: medium — 8-K filings often contain significant corporate and financial information that can impact stock price, necessitating careful review.

Key Players & Entities

FAQ

What specific material definitive agreement did BioCryst Pharmaceuticals enter into?

The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text.

What are the key updates regarding BioCryst's results of operations and financial condition?

The filing states that results of operations and financial condition are being reported, but the specific financial details are not included in the provided text.

Were there any departures or appointments of directors or officers?

Yes, the filing indicates information regarding the departure of directors or certain officers, election of directors, and appointment of certain officers, as well as compensatory arrangements.

What other events are being reported by BioCryst Pharmaceuticals?

The filing lists 'Other Events' as an item being reported, but the specific nature of these events is not detailed in the provided text.

What types of exhibits are included with this 8-K filing?

The filing mentions 'Financial Statements and Exhibits' are being included, but the specific list or content of these exhibits is not detailed in the provided text.

Filing Stats: 4,658 words · 19 min read · ~16 pages · Grade level 18.4 · Accepted 2025-10-14 07:10:18

Key Financial Figures

Filing Documents

01

Item 1.01. Entry into a Material Definitive Agreement. Agreement and Plan of Merger On October 14, 2025, BioCryst Pharmaceuticals, Inc., a Delaware corporation (" BioCryst "), Axel Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BioCryst (" Merger Sub "), and Astria Therapeutics, Inc., a Delaware corporation (" Astria "), entered into an Agreement and Plan of Merger (the " Merger Agreement "). Pursuant to the Merger Agreement, and subject to the satisfaction or waiver of the conditions specified therein, at the Effective Time (as defined below), Merger Sub will merge with and into Astria, with Astria surviving the Merger as a wholly owned subsidiary of BioCryst (the " Merger "). Merger Consideration Time "), each share of common stock, par value $0.001 per share, of Astria (" Astria Common Stock ") issued and outstanding immediately prior to the Effective Time (subject to certain exceptions, including shares of Astria Common Stock owned by stockholders of Astria who have not voted in favor of the adoption of the Merger Agreement and have properly exercised appraisal rights in accordance with Section 262 of the General Corporation Law of the State of Delaware) will be converted into the right to receive (i) 0.59 (the " Exchange Ratio ") of a share of common stock, par value $0.01 per share, of BioCryst (" BioCryst Common Stock ") and, if applicable, cash in lieu of fractional shares, and (ii) $8.55 in cash, without interest (the " Per Share Cash Amount "), subject to adjustment as described below and subject to applicable withholding taxes (the consideration described in the foregoing clauses (i) and (ii), collectively, the " Merger Consideration "). Pursuant to the Merger Agreement, at the Effective Time, each share of Series X Convertible Preferred Stock, par value $0.001 per share, of Astria (the " Series X Preferred

02

Item 2.02. Results of Operations and Financial Condition. During the Investor Call (as defined below), BioCryst will announce that the third quarter ended September 30, 2025 was another strong quarter for ORLADEYO demand, in line with what has been observed over the past two years, with no impact from new competition. The information in this Item 2.02 of this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by BioCryst under the Securities Act, or the Exchange Act, except as expressly set forth by specific reference in such filing.

02

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 13, 2025, subject to certain conditions specified in the Merger Agreement (including the occurrence of the Effective Time), BioCryst's board of directors (the " BioCryst Board ") approved an increase in the size of the BioCryst Board and elected Jill C. Milne, Ph.D., President, Chief Executive Officer and member of the board of directors of Astria, to fill the vacancy created by the enlargement of the BioCryst Board. Dr. Milne's initial term will expire at BioCryst's annual meeting of stockholders in 2028. Pursuant to BioCryst's Stock Incentive Plan and in accordance with BioCryst's amended and restated director compensation policy, Dr. Milne will receive an initial equity grant having a value equal to $500,000 upon joining the BioCryst Board, prorated based on the effective date of her appointment relative to BioCryst's next annual meeting of stockholders and payable 60% in stock options and 40% in restricted stock units. She will also receive compensation consistent with BioCryst's amended and restated director compensation policy as described in BioCryst's proxy statement for its 2025 annual meeting. Dr. Milne has no direct or indirect interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K and, other than the Merger Agreement, there are no arrangements or understandings pursuant to which she was selected as a director. At present, there is no expectation as to which committees of the BioCryst Board Dr. Milne will initially serve on, if any.

01

Item 8.01. Other Events. On October 8, 2025, BioCryst paid off in full and terminated that certain Loan Agreement, dated as of April 17, 2023, among BioCryst, the other guarantors from time to time party thereto, BioPharma Credit PLC, as collateral agent, and BPCR Limited Partnership and BioPharma Credit Investments V (Master) LP, as lenders (as amended, restated, amended and restated, supplemented or otherwise modified from time to time). On October 14, 2025, BioCryst and Astria issued a joint press release announcing the execution of the Merger Agreement. A copy of the press release is attached as Exhibit 99.2 hereto and is incorporated herein by reference. On October 14, 2025, BioCryst released a presentation to investors about the Merger. A copy of the investor presentation is attached as Exhibit 99.3 hereto and is incorporated herein by reference. BioCryst will conduct a conference call and webcast to discuss the proposed transaction at 8:00 a.m., Eastern Time, on October 14, 2025 (the " Investor Call "). Cautionary Statement Regarding Forward-Looking Statements identified as, forward-looking statements for purposes of the safe harbor provided by Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements are based on, among other things, BioCryst management's and Astria management's beliefs, assumptions, current expectations, estimates and projections about the economy and BioCryst and Astria and the industry in which they operate. Words and phrases such as "may," "approximately," "continue," "should," "expects," "projects," "anticipates," "is likely," "look ahead," "look forward," "believes," "will," "intends," "estimates," "strategy," "plan," "could," "potential," "possible" and variations of such words and similar expressions are intended to identify such forward-looki

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing